Clinical Trials Logo

Clinical Trial Summary

Severe acute pancreatitis (SAP) has a mortality of up to 42%. The outcome of SAP is related to the development of SIRS and consecutive organ failures. Due to the lack of a causative therapy except the removal of bile duct stones, therapy is predominantly symptomatic.

With regard to a marked inflammatory response ("cytokine storm") during the early phase of SAP extracorporeal cytokine removal is a promising therapeutic approach.

This prospective case control study investigates the impact of early extracorporeal cytokine adsorption with the CytoSorb®-device on haemodynamics (primary endpoint) and several secondary outcomes.


Clinical Trial Description

Severe acute pancreatitis (SAP) has a mortality of up to 42%. The outcome of SAP is related to the development of SIRS and consecutive organ failures. Due to the lack of a causative therapy except the removal of bile duct stones, therapy is predominantly symptomatic.

Severity and mortality are associated to an early systemic inflammatory response syndrome (SIRS) and to septic complications at a later stage of disease.

With regard to a marked inflammatory response ("cytokine storm") during the early phase of SAP extracorporeal cytokine removal is a promising therapeutic approach.

This prospective case control study investigates the impact of early extracorporeal cytokine adsorption with the CytoSorb® device on haemodynamics (primary endpoint) and several secondary outcomes.

Patients with high probability of SAP (APACHE-II-score ≥10) are eligible for 7 days after the onset of pain.

The patients will be treated for 48h with two consecutive 24h sessions of cytokine absorption with the CytoSorb®-device.

All patients will be under haemodynamic Monitoring with transpulmonary thermodilution The primary endpoint is defined as an improvement of the vasopressor dependency index of ≥20% (if no vasoactive drugs are used at baseline, the cardiac power index cardiac power index (CPI) will be used as primary endpoint).

The outcome analysis will be based on comparison of the incidence of the primary endpoint in 30 Intervention patients compared to 60 matched controls. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03082469
Study type Interventional
Source Technische Universität München
Contact Wolfgang Huber, Professor
Phone ++49-89-4140-5214
Email Wolfgang.Huber@tum.de
Status Not yet recruiting
Phase Phase 4
Start date March 15, 2017
Completion date July 2018

See also
  Status Clinical Trial Phase
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT01686776 - A Prospective Validation Study of Albumin Kinetics With Tracer 123 I-HSA Phase 3
Recruiting NCT02922998 - CD64 and Antibiotics in Human Sepsis N/A
Completed NCT02083198 - Effects of IV Chloride Content on Outcomes N/A
Completed NCT01410578 - The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis and Bacteremia Among Patients With a FUO N/A
Recruiting NCT05023954 - mSEP: Testing of Physiological and Immune-metabolic Blood Markers for Maternal Sepsis
Completed NCT00554021 - Infections Related Central Venous Catheters N/A
Not yet recruiting NCT05142813 - A Blood Test to Diagnose Sepsis in Symptomatic Adults and Children
Recruiting NCT01493466 - Serum Proteomics Analysis for Sepsis N/A
Recruiting NCT01155674 - Innate Immune Functions of Immature Neutrophils N/A
Recruiting NCT01493492 - Urinary Proteomics Analysis for Sepsis and Prognosis N/A
Completed NCT01333657 - The Application of Soluble Triggering Receptor Expressed on Myeloid Cells-1 in Sepsis & Relevant Acute Kidney Injuries N/A
Completed NCT01236703 - Hematological Infection Score Compared to the Hospital Standard for Diagnosis of SIRS or Sepsis on ICU N/A
Terminated NCT02704871 - The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS N/A
Completed NCT04901338 - Cytokine Hemoadsorption in ECMO Patients
Completed NCT01585909 - Evaluation of Intestinal Brush Border Enzyme Function in Critically Ill Patients N/A
Completed NCT01649440 - Sepsis Metabolomics N/A
Completed NCT03784521 - Efficacy of Intravenous In-line Filter in Patient Undergoing Cardiac Surgery N/A
Completed NCT04724044 - Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia Phase 3
Completed NCT02052895 - Utility of Presepsin in Distinguishing Between Sepsis and SIRS